Skip to content
DataLookout
Menu

NECESSITYNCT05113004

New Clinical End-points in Patients With Primary Sjögren's Syndrome

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Feb 1, 2024 to Apr 1, 2025
    • Study completion date: Apr 5, 2025 to Oct 1, 2025
    v4
  3. Minor Study sites: 1 to 7v3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Oct 5, 2024 to Feb 1, 2024
    • Start date changed from estimate of Jan 5, 2022 to Jan 20, 2022
    • Study description expanded, about 1 word
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohort 1. Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm.
Timeframe: During the 24 weeks of the trials
Cohort 2. Proportion of patients achieving a response according to preliminary STAR at week 24 between each active treatment arm and placebo arm.
Timeframe: During the 24 weeks of the trials

Arms and interventions

Arm 1Placebo comparator

Cohort 1 : Patients with High levels of symptoms and low disease activity receive : Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d

Arm 2Other

Cohort 1 : Patients with High levels of symptoms and low disease activity receive : Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d

Arm 3Other

Cohort 1 : Patients with High levels of symptoms and low disease activity receive : Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d

Arm 4Placebo comparator

Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive : Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d

Arm 5Other

Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive : Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d

Arm 6Other

Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive : Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d

Drugs: Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate mofetil 2000mg/d, Placebo of Hydroxychloroquine 400mg/d, Placebo of Leflunomide 20mg/d, Placebo of Mycophenolate mofetil 2000mg/d

Sites

7 sites in 1 country